# Acute Agitation Aggression Treatment Market

> Acute Agitation and Aggression Treatment Market Research Report Information by Drug Class (First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Indication (Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation and Aggression, Alcohol Withdrawal, and Others), by End User (Hospitals & Clinics, Psychiatric Care Facilities, and Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.95%
- **2024:** $ 6.22 Billion
- **2025:** $ 6.66 Billion
- **2035:** $ 13.04 Billion
- **Key Players:** Johnson & Johnson (US), Pfizer (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), AstraZeneca (GB), Roche (CH), Novartis (CH), Otsuka Pharmaceutical (JP), H. Lundbeck A/S (DK)

**Report ID:** MRFR/Pharma/7365-CR · **Pages:** 128 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** April 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/acute-agitation-aggression-treatment-market-8837

---

## Market Summary

## **Acute Agitation and Aggression Treatment Market Overview**

As per MRFR analysis, the Acute Agitation and Aggression Treatment Market Size was estimated at 6.22 (USD Billion) in 2024. The Acute Agitation and Aggression Treatment Market Industry is expected to grow from 6.66 (USD Billion) in 2025 to 12.19 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.95% during the forecast period (2025 - 2034). 

The rising prevalence of acute agitation and aggression and the increase in focus on creating awareness about agitation and aggression are driving the market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

April 2022: BioXcel Therapeutics, Inc., a biopharmaceutical company that uses artificial intelligence (AI) techniques to discover and create groundbreaking medicines in neuroscience and immuno-oncology, has received approval from the U.S. Food and Drug Administration (FDA) for IGALMI™ (dexmedetomidine) sublingual film. This film is intended for the immediate treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults.1 Patients can self-administer IGALMI under the guidance of a healthcare provider.

## **Acute Agitation and Aggression Treatment Market Trends**

Acute agitation is a state of high anxiety, intense arousal, and high motor activity that can arise from several psychiatric and medical conditions such as anxiety, dementia, and insomnia. The rising prevalence of acute agitation and aggression demands the discovery of newer and more effective drugs for their treatment. Moreover, the growing incidence of schizophrenia, dementia, depression, bipolar disorder, drug-induced agitation, and other mental illnesses is anticipated to fuel the market growth during the forecast period.

For instance, according to the National Institute of Mental Health (US), in 2020, serious mental illness (SM)I was expected to affect 14.2 million adults in the US aged 18 and above. Females had a higher prevalence of SMI (7.0%) than males (4.2%). Stress, workplace stress, depression, endocrine disorders, electrolyte imbalance, and other factors are the major causes of acute agitation and aggression.

Furthermore, according to the World Health Organization (WHO), dementia currently affects approximately 10 million people in Europe, with the prevalence expected to double by 2030. Hence, the increasing prevalence of acute agitation and rising burden of psychological illness & mortality will drive the market growth during the forecast period.

## **Acute Agitation and Aggression Treatment Market Segment Insights**

### **Acute Agitation and Aggression Treatment Drug Class Insights**

The Acute Agitation and Aggression Treatment Market segmentation, based on drug class, includes first-generation anti-psychotics, second-generation anti-psychotics, benzodiazepines, and others. The second-generation antipsychotics (SGA) segment is to hold the majority share in 2022 in the Acute Agitation and Aggression Treatment Market revenue. This is due to the effective medication giving the best results for patients suffering from agitation and aggression, and other related disorders. Moreover, second-generation antipsychotics (SGA), also called atypical antipsychotics, are commonly used in the acute setting. Furthermore, SGAs are also used in children with severe autism exhibiting behavioral disturbances though repeatedly giving antipsychotics is not preferred.

**September 2021:**Otsuka Holdings Co., Ltd (Japan) announced a worldwide collaboration and license agreement with Sumitomo Dainippon Pharma (Japan) for four psychiatry and neurology compounds development codes, including SEP-363856（ulotaront), SEP-4199, SEP-378614, and SEP-380135, which is further augmenting the market growth.

### **Acute Agitation and Aggression Treatment Route of Administration Insights**

The Acute Agitation and Aggression Treatment Market segmentation is based on a route of administration, that includes oral, intramuscular, and others. The oral segment has dominated the market in 2022 and the others segment is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the rising use of agitation treatment drugs in oral form. In addition, orally administered medication are easier route of administration for patients and is preferred as it offers a greater sense of control to patients.

**Figure 2: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

### **Acute Agitation and Aggression Treatment Indication Insights**

The Acute Agitation and Aggression Treatment Market segmentation, based on indication, includes schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation and aggression, alcohol withdrawal, and others. The dementia segment is to hold the majority share in 2022 in the Acute Agitation and Aggression Treatment Market revenue. This is due to the increase in the incidences of dementia among the geriatric population, the rise in the burden of mental illness, a surge in agitation in patients, and a rise in prescriptions of anti-psychotics.

According to the Centers for Disease Control and Prevention, dementia is not a particular disease but is rather a general term for the reduced ability to remember, think, or make choices that interfere with everyday activities. Moreover, it only affects older adults over the age of 65.

### **Acute Agitation and Aggression Treatment End User Insights**

The Acute Agitation and Aggression Treatment Market segmentation is based on the end user that includes hospitals & clinics, psychiatric care facilities, and others. The hospitals & clinics segment has dominated the market in 2022 and psychiatric care facilities is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the rise in the geriatric population, and the increasing number of hospitals. Today most large general hospitals have a psychiatric unit. Most hospitals have adult mental health, old age, and learning disability link psychiatry teams. If needed, they are ready to attend to crises immediately.

The hospital stay of many persons with chronic mental illness has been shortened by modern medication and better understanding on the part of the public.

**February 2021:**Sapravato (Esketamine Nasal Spray) received Johnson & Johnson Services, Inc’s (US) authorization in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder.

### **Acute Agitation and Aggression Treatment Regional Insights**

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American acute agitation and aggression treatment market accounted for the largest market share in 2022. This is attributed to the growing focus on spreading awareness among people regarding treatment associated with agitation and aggression, well-established healthcare infrastructure, the rise in the economic burden of mental illness, presence of leading market players in the region.

Additionally, the rise in the focus of players on research and development in the region is also expected to increase demand for acute agitation and aggression treatment across North America.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil

**Figure 3: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET BY REGION 2022 & 2032**

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

Europe acute agitation and aggression treatment market is expected to account for the second-largest market share due to the increasing prevalence of various health disorders such as dementia, alcohol dependence, depression, and bipolar disorders in the region. Further, the Germany acute agitation and aggression treatment market was attributed to holding the largest market share, and the UK acute agitation and aggression treatment market is expected to fastest-growing market in the European region.

The Asia-Pacific acute agitation and aggression treatment market is expected to grow at the fastest rate from 2023 to 2032. This is due to the rise in the geriatric population and increase in agitation in patients, and ongoing research on the development of novel treatments for agitation in the region. Moreover, China’s acute agitation and aggression treatment market is expected to hold the largest market share, and India acute agitation and aggression treatment market is expected fastest-growing market in the Asia-Pacific region.

Furthermore, rise in the prevalence of mental illnesses such as schizophrenia and bipolar disorder, and the focus of market players on India and Japan to exploit opportunities in these emerging markets. will accelerate growth in the acute agitation and aggression treatment market.

The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of acute agitation and aggression treatment in the Middle East and Africa are the increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development that boost the market growth in the Middle East. On the other hand, the growth opportunities in developing countries such as South Africa, UAE, and Saudi Arabia are estimated to provide lucrative growth opportunities to the market players.

## **Acute Agitation and Aggression Treatment Key Market Players & Competitive Insights**

The Acute Agitation and Aggression Treatment Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Eli Lilly and Company (US), Pfizer Inc (US), GlaxoSmithKline plc (UK), and Teva Pharmaceutical Industries Ltd (Israel) dominate the Acute Agitation and Aggression Treatment Market due to product differentiation, financial stability, strategic developments, and diversified regional presence.

The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global acute agitation and aggression treatment industry to benefit clients and expand the acute agitation and aggression treatment market sector is to manufacture locally to reduce operating costs.

GlaxoSmithKline is engaged in R&D and manufacturing innovative pharmaceutical medicine, vaccines, and consumer healthcare products across the globe. It operates through four segments, namely, pharmaceuticals, pharmaceuticals R&D, vaccines, and consumer healthcare. Its pharmaceutical segment offers innovative and well-established medicines in respiratory, human immunodeficiency virus (HIV), including lupus, psychiatry, neurology, urology, & anti-infectives, immunoinflamation, and oncology. Its vaccine segment includes pneumococcal disease, meningitis, hepatitis, rotavirus, whooping, cough, and influenza. The company has a significant global presence in more than 150 countries, including 87 manufacturing sites in 36 countries and large R&D centers in the UK, US, Spain, Belgium, and China.

For instance, in July 2021, GlaxoSmithKline plc (UK) collaborated with Alector (US) to co-develop progranulin-elevating monoclonal antibodies, AL001, and AL101, to treat neurodegenerative disorders. This helped the company to retain exclusive commercialization rights outside the US.

Also, Teva Pharmaceutical Industries Ltd (Israel) is one of the leaders in pharmaceutical industries engaged in developing and providing services in generic medicines. The company has more than 1,800 molecules used to create an extensive variety of generic products in almost every therapeutic area. It is specialized in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women’s health, and biologics. It operates in the following regions–North America, Latin America, Europe, Japan, and South Korea. It has 26 FDA-approved plants, and 31 European Medicines Agency (EMA) approved plants worldwide.

### **Key Companies in the Acute Agitation and Aggression Treatment Market include**

## **Acute Agitation and Aggression Treatment Industry Developments**

In July 2022, Impel Pharmaceuticals commenced a Phase 2a proof-of-concept study for INP105, a nasal formulation of olanzapine, aimed at addressing acute agitation in individuals diagnosed with autism spectrum disorder (ASD). This investigation utilizes Impel's unique Precision Olfactory Delivery (POD) technology, designed to administer drugs to the upper nasal cavity, providing a non-invasive approach with a swift onset of action.

Otsuka Pharmaceutical Co., Ltd. has established itself as a significant contributor in the market for treating acute agitation and aggression. In June 2022, the company, in partnership with H. Lundbeck A/S, reported favorable outcomes from a Phase III clinical trial of brexpiprazole aimed at addressing agitation in individuals with Alzheimer's dementia.

In December 2024, Axsome Therapeutics revealed its intention to pursue marketing approval for its oral medication, AXS-05, aimed at addressing agitation in individuals diagnosed with Alzheimer's disease. The medication showed considerable delays in relapse time and provided symptom relief in the majority of the four late-stage studies carried out.

## **Acute Agitation and Aggression Treatment Market Segmentation**

### **Acute Agitation and Aggression Treatment Drug Class Outlook**

### **Acute Agitation and Aggression Treatment Route of Administration Outlook**

### **Acute Agitation and Aggression Treatment Indication Outlook**

### **Acute Agitation and Aggression Treatment End User Outlook**

### **Acute Agitation and Aggression Treatment Regional Outlook**

**North America**

**Europe**

**Asia-Pacific**

**Rest of the World**

## Market Drivers

### Rising Prevalence of Mental Health Disorders

The increasing incidence of mental health disorders globally is a primary driver of the Global Acute Agitation and Aggression Treatment Market Industry. Conditions such as schizophrenia, bipolar disorder, and severe depression contribute significantly to acute agitation and aggression. According to the World Health Organization, mental health disorders affect approximately 1 in 4 individuals at some point in their lives. This growing prevalence necessitates effective treatment options, thereby expanding the market. As awareness of mental health issues rises, the demand for innovative treatment solutions is likely to increase, further propelling market growth.

## Future Outlook

The Acute Agitation Aggression Treatment Market is projected to grow at a 6.95% CAGR from 2025 to 2035, driven by increasing prevalence of [mental health](https://www.marketresearchfuture.com/reports/mental-health-market-12354) disorders and advancements in treatment methodologies.

**New opportunities:**

- Development of telehealth platforms for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) Integration of AI-driven analytics for personalized treatment plans Expansion of training programs for healthcare professionals in de-escalation techniques

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms.

## Segment Insights

### By Treatment Type: Pharmacological Treatment (Largest) vs. Psychological Intervention (Fastest-Growing)

In the Acute Agitation Aggression Treatment Market, the treatment segment is composed of various approaches, each holding distinct market shares. Pharmacological Treatment remains the largest segment, offering a range of antipsychotic and sedative medications widely utilized in clinical settings. Meanwhile, Psychological Interventions, which include therapeutic techniques such as cognitive behavioral therapy, are gaining traction, attributed to their effectiveness in managing aggression and agitation without the need for medication. As awareness of mental health treatment options grows, both segments are prominent in the market landscape.

Pharmacological Treatment: (Dominant) vs. Psychological Intervention (Emerging)

Pharmacological Treatment is currently the dominant approach in managing acute agitation and aggression, primarily due to its quick efficacy in symptom control. This segment includes various medications that provide immediate relief and are preferred in emergency settings. In contrast, Psychological Interventions have emerged as a crucial component of treatment, focusing on holistic and long-term management of aggressive behaviors. This shift reflects a growing acknowledgment of the importance of mental health strategies, particularly in enhancing patient outcomes and reducing reliance on medication. The integration of both methods signifies an evolving treatment paradigm within the market, catering to diverse patient needs while emphasizing safety and therapeutic efficacy.

### By Patient Demographics: Age Group (Largest) vs. Severity of Condition (Fastest-Growing)

In the Acute Agitation Aggression Treatment Market, the age group segment holds a significant share, with middle-aged adults accounting for the largest proportion of patients requiring treatment. This demographic is predominantly affected by various conditions leading to acute agitation and aggression episodes. The distribution also shows a substantial presence of the elderly population, who require specialized care due to age-related factors, thus impacting the overall market dynamics pertaining to age-related treatment options. The severity of condition also plays a crucial role, showing the fastest growth in the market as an increasing number of patients present with severe agitation and aggression symptoms. This trend can be attributed to heightened awareness among healthcare providers and patients, leading to increased diagnosis rates. Moreover, the growth is driven by advancements in treatment options and emerging therapies that specifically address severe cases of agitation and aggression, opening new avenues for market expansion.

Age Group: Middle-Aged Adults (Dominant) vs. Severity of Condition: Severe Cases (Emerging)

Within the Acute Agitation Aggression Treatment Market, middle-aged adults emerge as the dominant demographic, as they frequently present with disorders such as schizophrenia, bipolar disorder, and major depressive disorders that are associated with symptoms of acute agitation. This age group often receives focused treatment approaches, making it a stable segment for healthcare providers. In contrast, severe cases of agitation are considered an emerging trend, as healthcare systems are now adapting to better strategies for management and intervention. This growth is indicative of a broader understanding of the complexities surrounding severe behavioral symptoms and the need for tailored treatment, thus driving innovations and enhancing care frameworks for this subset of patients.

### By Healthcare Setting: Inpatient Facility (Largest) vs. Emergency Department (Fastest-Growing)

In the Acute Agitation Aggression Treatment Market, the distribution among healthcare settings reveals that the Inpatient Facility segment accounts for the largest market share. This is primarily due to the comprehensive care and immediate intervention facilities that these institutions provide. Inpatient Facilities are equipped with the necessary resources and trained personnel to manage acute cases effectively, which fosters a stable patient environment and a structured treatment approach. Conversely, the Emergency Department is emerging rapidly as the fastest-growing segment. This growth is driven by an increasing number of patients presenting acute agitation issues, emphasizing the need for prompt treatment within emergency settings. Factors such as rising awareness of mental health challenges and the urgency of handling aggressive behavior contribute significantly to this surge in demand for services in emergency environments.

Inpatient Facility (Dominant) vs. Outpatient Clinic (Emerging)

The Inpatient Facility segment stands as the dominant force in the Acute Agitation Aggression Treatment Market. Its characteristics include a robust infrastructure designed for critical care, access to multi-disciplinary teams, and rigorous treatment protocols that enhance patient safety. Additionally, Inpatient Facilities benefit from comprehensive management resources, including pharmaceuticals and behavioral therapies tailored to patients with severe cases. On the other hand, the Outpatient Clinic segment is emerging as a formidable alternative, particularly for less severe cases. These clinics offer more accessible, cost-effective treatment options and cater to patients requiring ongoing management without hospitalization. The shift towards outpatient care reflects broader healthcare trends emphasizing patient convenience and resource optimization.

### By Administration Route: Intravenous (Largest) vs. Intramuscular (Fastest-Growing)

The Acute Agitation Aggression Treatment Market features a variety of administration routes, with intravenous (IV) methods holding the largest market share. IV administration is favored in acute settings due to its rapid onset of action, ensuring timely relief from severe agitation and aggression. Oral and subcutaneous routes, while significant, lag behind in terms of immediate effect and patient compliance during crises, impacting their overall market share. The prevailing trend illustrates a preference for IV solutions in emergency departments, leading to its dominant position within this segment. In terms of growth trends, the intravenous segment benefits from increased awareness and advocacy for swift intervention protocols. Furthermore, the rising incidence of acute agitation in various patient populations propels demand for quick-acting treatments. The intramuscular route is emerging as a rapidly growing alternative, attracting attention for its balance between speed and ease of administration, particularly in non-hospital settings, thus capturing significant growth opportunities alongside the established IV segment.

Intravenous (Dominant) vs. Intramuscular (Emerging)

The intravenous (IV) administration route is characterized by its rapid delivery of medications directly into the bloodstream, providing immediate therapeutic effects critical in managing acute agitation and aggression. This route is prevalent in emergency departments, where speed is essential. Additionally, IV administration allows for precise control of dosage, which is vital in treating varying intensity levels of aggression. Conversely, the intramuscular (IM) route is gaining traction as an emerging option due to its simplicity and effectiveness in scenarios where IV access may be challenging. IM administration offers a quicker onset than oral routes while being less invasive than IV methods, thus appealing to both healthcare providers and patients in situations that require effective yet manageable interventions.

### By Duration of Treatment: Short-term (Largest) vs. Long-term (Fastest-Growing)

The Acute Agitation Aggression Treatment Market is primarily segmented into short-term, long-term, crisis intervention, and maintenance therapy. Among these segments, short-term treatment is recognized as the largest, catering particularly to acute episodes of agitation where immediate intervention is crucial. Conversely, long-term treatment is rapidly gaining traction, supported by increasing awareness and the need for ongoing management of chronic agitation issues. As healthcare systems evolve, these differentiations in treatment duration are gaining more attention.

Short-term (Dominant) vs. Long-term (Emerging)

Short-term treatment methods serve as the dominant approach in the Acute Agitation Aggression Treatment Market due to their effectiveness in managing immediate crises. These treatments focus on rapid stabilization, often employing pharmacological interventions. In contrast, long-term approaches are emerging as essential for sustained mental health management, integrating therapeutic practices and community support. The shift towards long-term solutions is influenced by the significant benefits of ongoing care, reducing relapse rates and promoting overall well-being. As a result, healthcare providers are increasingly adopting long-term strategies to complement immediate care, leading to a more holistic treatment landscape.

## Regional Market Share Analysis

### North America : Market Leader in Treatment

North America is poised to maintain its leadership in the Acute Agitation Aggression Treatment Market, holding a significant market share of 3.5B in 2024. The region's growth is driven by increasing incidences of mental health disorders, heightened awareness, and advancements in treatment methodologies. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring that innovative therapies are swiftly approved and accessible to patients. The competitive landscape in North America is robust, featuring key players such as Johnson & Johnson, Pfizer, and Eli Lilly. These companies are at the forefront of developing effective treatments, leveraging cutting-edge research and development. The presence of established healthcare infrastructure and a strong focus on mental health initiatives contribute to the region's dominance, making it a critical hub for innovation and patient care.

### Europe : Emerging Market Potential

Europe is witnessing a growing demand for Acute Agitation Aggression Treatment, with a market size of 1.5B in 2024. Factors such as increasing mental health awareness, supportive healthcare policies, and the integration of mental health services into primary care are driving this growth. The European Medicines Agency (EMA) plays a crucial role in regulating and approving new treatments, ensuring that patients have access to effective therapies in a timely manner. Leading countries in this region include Germany, France, and the UK, where significant investments in mental health services are being made. The competitive landscape features major players like AstraZeneca and Roche, who are actively involved in research and development. The collaboration between public and private sectors is enhancing treatment options, making Europe a promising market for future growth in this sector.

### Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is emerging as a significant player in the Acute Agitation Aggression Treatment Market, with a market size of 1.2B in 2024. The growth is fueled by rising awareness of mental health issues, increasing healthcare expenditure, and government initiatives aimed at improving mental health services. Countries like Japan and Australia are leading the charge, supported by favorable regulatory environments that encourage the development of new therapies. The competitive landscape is evolving, with key players such as Otsuka Pharmaceutical and H. Lundbeck A/S making strides in the market. The region's diverse population and varying healthcare needs present both challenges and opportunities for companies. As mental health becomes a priority, the Asia-Pacific market is expected to witness substantial growth, driven by innovation and increased access to treatments.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents an untapped market for Acute Agitation Aggression Treatment, with a market size of only 0.02B in 2024. The growth in this region is hindered by limited healthcare infrastructure, stigma surrounding mental health, and insufficient regulatory frameworks. However, increasing awareness and initiatives by governments and NGOs are beginning to address these challenges, paving the way for future growth in mental health services. Countries like South Africa and the UAE are making efforts to improve mental health care access, but the competitive landscape remains sparse. Key players are beginning to explore opportunities in this region, focusing on partnerships and collaborations to enhance treatment availability. As mental health awareness grows, the potential for market expansion in the Middle East and Africa is significant, albeit gradual.

## Competitive Benchmarking

The Acute Agitation Aggression Treatment Market is characterized by a dynamic competitive landscape, driven by increasing incidences of mental health disorders and a growing recognition of the need for effective treatment options. Key players such as Johnson & Johnson (US), Pfizer (US), and Eli Lilly and Company (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Johnson & Johnson (US) focuses on innovation through the development of novel therapeutic agents, while Pfizer (US) emphasizes strategic partnerships to expand its product portfolio. Eli Lilly and Company (US) is investing heavily in research and development to create targeted therapies, thereby positioning itself as a leader in the treatment of acute agitation and aggression.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing. The collective influence of these major companies shapes the market dynamics, as they leverage their resources to enhance product availability and accessibility.
In November Johnson & Johnson (US) announced a collaboration with a leading technology firm to integrate AI-driven analytics into their treatment protocols. This strategic move is likely to enhance patient outcomes by personalizing treatment plans based on real-time data, thereby reinforcing Johnson & Johnson's commitment to innovation in mental health care. The integration of technology into treatment methodologies may set a new standard in the industry.
In October Pfizer (US) launched a new initiative aimed at expanding access to its acute agitation treatment in underserved regions. This initiative, which includes partnerships with local healthcare providers, underscores Pfizer's strategy to enhance its market footprint while addressing critical healthcare disparities. By focusing on accessibility, Pfizer not only strengthens its market position but also aligns with global health priorities.
In September Eli Lilly and Company (US) received regulatory approval for a new formulation of its leading treatment for acute agitation. This approval is pivotal as it allows for a more flexible dosing regimen, potentially increasing patient adherence and satisfaction. Eli Lilly's proactive approach in refining its product offerings demonstrates its commitment to meeting evolving patient needs and maintaining a competitive edge.
As of December the competitive trends in the Acute Agitation Aggression Treatment Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing innovation and expanding market reach. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to changing market demands.

## Recent News & Developments

In July 2022, Impel Pharmaceuticals commenced a Phase 2a proof-of-concept study for INP105, a nasal formulation of [olanzapine](https://www.marketresearchfuture.com/reports/olanzapine-market-718), aimed at addressing acute agitation in individuals diagnosed with autism spectrum disorder (ASD). This investigation utilizes Impel's unique Precision Olfactory Delivery (POD) technology, designed to administer drugs to the upper nasal cavity, providing a non-invasive approach with a swift onset of action.

Otsuka Pharmaceutical Co., Ltd. has established itself as a significant contributor in the market for treating acute agitation and aggression. In June 2022, the company, in partnership with H. Lundbeck A/S, reported favorable outcomes from a Phase III clinical trial of brexpiprazole aimed at addressing agitation in individuals with Alzheimer's dementia.

In December 2024, Axsome Therapeutics revealed its intention to pursue marketing approval for its oral medication, AXS-05, aimed at addressing agitation in individuals diagnosed with Alzheimer's disease. The medication showed considerable delays in relapse time and provided symptom relief in the majority of the four late-stage studies carried out.

## Report Scope

| MARKET SIZE 2024 | 6.22(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.66(USD Billion) |
| MARKET SIZE 2035 | 13.04(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.95% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Johnson & Johnson (US), Pfizer (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), AstraZeneca (GB), Roche (CH), Novartis (CH), Otsuka Pharmaceutical (JP), H. Lundbeck A/S (DK) |
| Segments Covered | Application, Treatment Type, Patient Demographics, Severity of Agitation, Duration of Treatment |
| Key Market Opportunities | Integration of digital therapeutics and telehealth solutions in the Acute Agitation Aggression Treatment Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Acute Agitation Aggression Treatment Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Acute Agitation Aggression Treatment Market?**
A: The market valuation was 6.22 USD Billion in 2024.

**Q: What is the projected market size for the Acute Agitation Aggression Treatment Market by 2035?**
A: The market is expected to reach 13.04 USD Billion by 2035.

**Q: What is the expected CAGR for the Acute Agitation Aggression Treatment Market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.95% during the forecast period 2025 - 2035.

**Q: Which treatment type had the highest valuation in 2024?**
A: Pharmacological Treatment had the highest valuation at 2.49 USD Billion in 2024.

**Q: How does the market for Psychological Intervention compare to Physical Restraint in 2024?**
A: Psychological Intervention was valued at 1.86 USD Billion, while Physical Restraint was at 1.12 USD Billion in 2024.

**Q: What demographic factors are influencing the Acute Agitation Aggression Treatment Market?**
A: Factors such as Age Group, Gender, Severity of Condition, and Co-morbidities are influencing the market.

**Q: What was the valuation of the Inpatient Facility segment in 2024?**
A: The Inpatient Facility segment was valued at 2.49 USD Billion in 2024.

**Q: Which administration route is projected to grow significantly by 2035?**
A: The Oral administration route is projected to grow significantly, reaching 3.91 USD Billion by 2035.

**Q: What is the expected market performance for Crisis Intervention by 2035?**
A: Crisis Intervention is expected to reach a valuation of 2.6 USD Billion by 2035.

**Q: Who are the key players in the Acute Agitation Aggression Treatment Market?**
A: Key players include Johnson & Johnson, Pfizer, Bristol-Myers Squibb, and Eli Lilly and Company.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/acute-agitation-aggression-treatment-market-8837*